Article
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia.
Leukemia - 1 Sept 2022
Soverini Simona, De Santis Sara, Martelli Margherita, Monaldi Cecilia, Castagnetti Fausto, Gugliotta Gabriele, Papayannidis Cristina, Mancini Manuela, Bruno Samantha, Venturi Claudia, Machova Polakova Katerina, Ernst Thomas, Maar Dianna, Corner Adam, Cavo Michele
Abstract excerpt
One of the indications for BCR::ABL1 mutation testing in chronic myeloid leukemia (CML) is when tyrosine kinase inhibitor therapy (TKI) needs to be changed for unsatisfactory response. In this study, we evaluated a droplet digital PCR (ddPCR)-based multiplex strategy for the detection and quantitation of transcripts harbouring mutations conferring resistance to second-generation TKIs (2GTKIs). Parallel...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.